Literature DB >> 12856289

Venous leg ulcer pain.

Siobhan Ryan1, Cathy Eager, R Gary Sibbald.   

Abstract

Venous disease and venous leg ulcers are frequently painful. The pain experienced may be constant or intermittent. Constant pain can originate from vascular structures (superficial, deep phlebitis), pitting edema, collagen (lipodermatosclerosis), infection, or scarring (atrophie blanche). Ulcer region pain is often episodic and may be due to surgical or other debridement procedures. Intermittent pain is often related to dressing removal or recent applications of new dressings. An approach to pain control will consider the cause of pain and utilize local measures, regional approaches to edema control, and systemic medication aimed at constant, episodic, or intermittent pain triggers.

Entities:  

Mesh:

Year:  2003        PMID: 12856289

Source DB:  PubMed          Journal:  Ostomy Wound Manage        ISSN: 0889-5899            Impact factor:   2.629


  4 in total

Review 1.  Minimising wound-related pain at dressing change: evidence-informed practice.

Authors:  Kevin Y Woo; Keith Harding; Patricia Price; Gary Sibbald
Journal:  Int Wound J       Date:  2008-06       Impact factor: 3.315

2.  The Canadian Bandaging Trial: Evidence-informed leg ulcer care and the effectiveness of two compression technologies.

Authors:  Margaret B Harrison; Elizabeth G Vandenkerkhof; Wilma M Hopman; Ian D Graham; Meg E Carley; E Andrea Nelson
Journal:  BMC Nurs       Date:  2011-10-13

Review 3.  Amelogenin, an extracellular matrix protein, in the treatment of venous leg ulcers and other hard-to-heal wounds: experimental and clinical evidence.

Authors:  Marco Romanelli; Valentina Dini; Peter Vowden; Magnus S Agren
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

Review 4.  The Role of Matrix Metalloproteinases in Diabetic Wound Healing in relation to Photobiomodulation.

Authors:  Sandra Matabi Ayuk; Heidi Abrahamse; Nicolette Nadene Houreld
Journal:  J Diabetes Res       Date:  2016-05-23       Impact factor: 4.011

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.